High-sensitivity C-reactive protein concentration in patients with myocardial infarction-environmental factors, and polymorphisms in interleukin-10 and CD14 genes

Clinical Chemistry and Laboratory Medicine

Volumn 45, Issue 7, 2007, Pages 855-861

  Lorenzová, Alena ^a   Staněk, Vladimír ^b   Gebauerová, Marie ^b   Bohuslavová, Romana ^b   Stávek, Petr ^b   Hubáček, Jaroslav A ^b,c   Lánská, Věra ^b   Poledne, Rudolf ^b,c  

^a CHARLES UNIVERSITY   (Czech Republic)

^b INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

^c Cardiovascular Research Center   (Czech Republic)

Author keywords

Atherosclerosis; CD14; Environmental factors; Genetic polymorphisms; Interleukin 10; Myocardial infarction

Indexed keywords

C REACTIVE PROTEIN; CD14 ANTIGEN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; LIPOPROTEIN;

ABDOMINAL OBESITY; ADULT; ALLELE; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CONTROL GROUP; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA POLYMORPHISM; EDUCATION; ENVIRONMENTAL FACTOR; GENOTYPE; HEART INFARCTION; HOSPITAL ADMISSION; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; SMOKING; STATISTICAL ANALYSIS;

ADULT; ALLELES; ANTIGENS, CD14; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-10; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; RISK FACTORS;

EID: 34447262545     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/CCLM.2007.157     Document Type: Article

References (38)

1. Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am Coll Cardiol 2005;45:1644-8.
2. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997;336:973-9.
3. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998;97:425-8.
4. Rost NS, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001;32:2575-9.
5. Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, et al. Association between C-reactive protein and features of the metabolic syndrome: a populationbased study. Diabetes Care 2000;23:1835-9.
6. Andreotti F, Porto I, Crea F, Maseri A. Inflammatory gene polymorphisms and ischaemic heart disease: review of population association studies. Heart 2002;87:107-12.
7. Pannacciulli N, Cantatore FP, Minenna A, Bellacicco M, Giorgino R, De Pergola G. C-reactive protein is independently associated with total body fat, central fat, and insulin resistance in adult women. Int J Obesity 2001;25:1416-20.
8. Lorenzova-Dvorakova A, Suchanek P, Havel PJ, Stavek P, Karasova L, Valenta Z, et al. The decrease in C-reactive protein concentration after moderate weight reduction is associated with changes in plasma lipids, but not interleukin-6 or adiponectin. Metabolism 2006;55:359-65.
9. Zee RYL, Ridker PM. Polymorphism in the human Creactive protein (CRP) gene, plasma concentrations of CRP, and the risk of future arterial thrombosis. Atherosclerosis 2002;162:217-9.
10. Jerrard-Dunne P, Sitzer M, Risley P, Buehler A, von Kegler S, Markus HS. Inflammatory gene load is associated with enhanced inflammation and early carotid atherosclerosis in smokers. Stroke 2004;35:2438-43.
11. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990;249:1431-3.
12. Hubacek JA, Pitha J, Skodova Z, Stanek V, Poledne R. C(-260)→T polymorphism in the promotor of the CD14 monocyte receptor gene as a risk factor for myocardial infarction. Circulation 1999;99:3218-20.
13. Unkelbach K, Gardemann A, Kostrzewa M, Phillip M, Tillmanns H, Haberbosch W. A new promoter polymorphism in the gene of lipolysaccharide receptor CD14 is associated with myocardial infarction in patients with low atherosclerotic risk profile. Arterioscler Thromb Vasc Biol 1999;19:932-8.
14. Zee RY, Lindpaintner K, Struk B, Hennekens CH, Ridker PM. A prospective evaluation of the CD14 C(-260)T gene polymorphism and the risk of myocardial infarction. Atherosclerosis 2001;154:699-702.
15. Hohda S, Kimura A, Sasaoka T, Hayashi T, Ueda K, Yasunami M, et al. Association study of CD14 polymorphism with myocardial infarction in a Japanese population. Jpn Heart J 2003;44:613-22.
16. Spits H, de Waal Malefyt R. Functional characterization of human IL-10. Int Arch Allergy Immunol 1992;99:8-15.
17. Perrey C, Pravica V, Sinnott PJ, Hutchinson IV. Genotyping for polymorphisms in interferon-g, interleukin-10, transforming growth factor-b1 and tumour necrosis factor-a genes: a technical report. Transpl Immunol 1998;6:193-7.
18. Suarez A, Castro P, Alonso R, Mozo L, Gutierrez C. Interindividual variations in constitutive interleukin-10 messenger RNA and protein levels and their association with genetic polymorphisms. Transplantation 2003;75:711-7.
19. Multinational monitoring of trends and determinants in cardiovascular diseases: "MONICA Project". Manual of operations WHO/MNC 82.2, November 1983.
20. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215-7.
21. Plaza DM, Fernandez D, Builes M, Villegas A, Garcia LF. Cytokine gene polymorphisms in heart transplantation: association of low IL-10 production genotype with Quilty effect. J Heart Lung Transplant 2003;22:851-6.
22. Donger C, Georges JL, Nicaud V, Morrison C, Evans A, Kee F, et al. New polymorphisms in the interleukin-10 gene - relationships to myocardial infarction. Eur J Clin Invest 2001;31:9-14.
23. Koch W, Kastrati A, Bottinger C, Mehilli J, von Beckerath N, Schomig A. Interleukin-10 and tumor necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction. Atherosclerosis 2001;159:137-44.
24. Koch W, Tiroch K, von Beckerath N, Schalming A, Kastrati A. Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting. Cytokine 2003;24:161-71.
25. Densem CG, Hutchinson IV, Yonan N, Brooks NH. Influence of interleukin-10 polymorphism on the development of coronary vasculopathy following cardiac transplantation. Transpl Immunol 2003;11:223-8.
26. Esposito K, Pontillo A, Giugliano F, Giugliano G, Marfella R, Nicoletti G, et al. Association of low interleukin-10 levels with the metabolic syndrome in obese women. J Clin Endocrinol Metab 2003;88:1055-8.
27. Heesen M, Blomeke B, Schluter B, Heussen N, Rossaint R, Kunz D. Lack of association between the -260 C→T promoter polymorphism of the endotoxin receptor CD14 gene and the CD14 density of unstimulated human monocytes and soluble CD14 plasma levels. Intensive Care Med 2001;27:1770-5.
28. Koenig W, Khuseyinova N, Hoffmann MM, Marz W, Frohlich M, Hoffmeister A, et al. CD14 C(-260)→T polymorphism, plasma levels of the soluble endotoxin receptor CD14, their association with chronic infections and risk of stable coronary artery disease. J Am Coll Cardiol 2002;40:34-42.
29. Shimada K, Miyauchi K, Mokuno H, Watanabe Y, Iwama Y, Shigekiyo M, et al. Promoter polymorphism in the CD14 gene and concentration of soluble CD14 in patients with in-stent restenosis after elective coronary stenting. Int J Cardiol 2004;94:87-92.
30. Morange PE, Tiret L, Saut N, Luc G, Arveiler D, Ferrieres J, et al. TLR4/Asp299Gly, CD14/C-260T, plasma levels of the soluble receptor CD14 and the risk of coronary heart disease: The PRIME Study. Eur J Hum Genet 2004;12:1041-9.
31. Amar J, Ruidavets JB, Bal dit Sollier C, Bongard V, Boccalon H, Chamontin B, et al. CD14 C(-260)T gene polymorphism, circulating soluble CD14 levels and arteriosclerosis. J Hypertens 2004;22:1523-8.
32. Humphries SE, Luong LA, Ogg MS, Hawe E, Miller GJ. The interleukin-6 -174 G/C promoter polymorphism is associated with risk of coronary heart disease and systolic blood pressure in healthy men. Eur Heart J 2001;22:2243-52.
33. Das UN. Is obesity an inflammatory condition? Nutrition 2001;17:953-66.
34. Ohsawa M, Okayama A, Nakamura M, Onoda T, Kato K, Itai K, et al. CRP levels are elevated in smokers but unrelated to the number of cigarettes and are decreased by long-term smoking cessation in male smokers. Prev Med 2005;41:651-6.
35. Ascer E, Bertolami MC, Venturinelli ML, Buccheri V, Souza J, Nicolau JC, et al. Atorvastatin reduces proinflammatory markers in hypercholesterolemic patients. Atherosclerosis 2004;177:161-6.
36. Li JJ, Chen MZ, Chen X, Fang CH. Rapid effects of simvastatin on lipid profile and C-reactive protein in patients with hypercholesterolemia. Clin Cardiol 2003;26:472-6.
37. Kim C, Eby E, Piette JD. Is education associated with mortality for breast cancer and cardiovascular disease among black and white women? Gend Med 2005;2:13-8.
38. Hoshida S, Nishino M, Takeda T, Tanouchi J, Yamada Y, Hori M. A persistent increase in C-reactive protein is a risk factor for restenosis in patients with stable angina who are not receiving statins. Atherosclerosis 2004;173:285-90.